Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score 18 weeks –25.0 with clozapine (250–600 mg/day) –24.2 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in Clinical Global Impression scale (CGI) Severity score 18 weeks –0.6 with clozapine (250–600 mg/day) –0.6 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	CGI Improvement score at endpoint 18 weeks 3.3 with clozapine (250–600 mg/day) 3.2 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant